• Commercial application of NeuroEEG and NeuroCap growing across ICUs, acute inpatient care and other emergency care in U.S.
• BRSF plans to launch devices in Canada
• Company expands footprint, plans patent applications in Latin America, Europe

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has unveiled the outlook for 2021. Brain Scientific continues to make strides within neurology by revolutionizing the brain diagnostic market with its groundbreaking technology. The company recently announced that its R&D efforts surged in 2020 with an investment of $275,926, which marks a 266% increase over 2019’s total of $103,616 (https://ibn.fm/Uiqs7). Despite a challenging year due to the pandemic, Brain Scientific reached significant milestones in 2020. A limited-scope commercial application of the NeuroEEG(TM) and NeuroCap(TM) is in progress in the United States, expected to be followed by the Canadian market. The initial entry market is identified as ICUs, acute inpatient care and other emergency facilities in the United States. As 2020 drew to a close, Brain Scientific announced that its NeuroCap would become available to the pediatric market in the United States. The child-size NeuroCap headset helps overcome the common challenges medical professionals face when conducting electroencephalograms (“EEG”) in pediatrics by bringing comfort, speed and reliability to the brain testing of children (https://ibn.fm/fWNps). At the end of last year, the company also filed a patent application for its new long-term monitoring EEG cap. It is a new flexible, full-head EEG cap developed as a response to the market demand for disposable EEG solution for prolonged EEG recordings (12 hours and longer). (https://ibn.fm/Z4Nqv). Brain Scientific is determined to bring its cutting-edge technology to the world and expand its footprint in the international landscape. Last year, the company established a wholly owned subsidiary in Russia and Europe (Poland) for product distribution and certification, and BRSF appears to have even bigger plans for the future. Within the next 24 months, the company expects to scale production in the United States, expand into the EU market and file international patent applications in Latin America, Europe and more. Future plans also include the introduction of a BRSF long-term monitoring cap and the addition of long-term monitoring, 24-channel EEG to its proprietary lineup of diagnostic devices. The third phase of development scheduled for 2021–2022 is also expected to be centered around the use of AI-powered data analysis to bring efficiency, consistency and accuracy to modern neurology diagnostics. This segment is intended to include the launch of data-storage capabilities for normalized data brain scans and the further development of the company’s planned AI neuro net while advancing application for minimally invasive graphene electrodes connected to the micro-EEG. At the forefront of neurology device technology, Brain Scientific appears poised to transform the neurology landscape and establish a new innovative norm for clinicians. For more information, visit the company’s website at www.BrainScientific.com. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• GLDFF names Scott Secord as director, Richard Caral as board observer
• Golden Leaf looks to benefit from cannabis space, capital markets experience
• Board appointments announced as company gears up to change name to Chalice Brands

Golden Leaf Holdings (CSE: GLH) (OTCQB: GLDFF), a premier, consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, has announced two changes to its impressive board of directors (https://ibn.fm/3AAxe). The company has appointed Scott Secord as a director and has named Richard Carl as board observer; both appointments will be effective immediately. “We are pleased to have Scott join the board immediately and for Richard to join as an observer to the board,” said Rick Miller, lead director of the company’s Board of Directors. “We look forward to benefitting from Scott’s experience in the cannabis space as well as Richard’s capital markets acumen and risk management expertise. Both bring many years of public company board and audit committee experience, as well strong capital markets experience.” Currently a managing partner of Shore Capital Sports & Entertainment, Secord also brings experience as an executive chairman and board member for RISE Life Science Corp. and president and CEO of Gaming Nation. Prior to his time at Gaming Nation, he also served as president and CEO of Pointstreak Sports Technologies, where he led the company to Fast 50 and Fast 500 award recognition from Deloitte Technology. Carl currently serves on the boards of several companies, including ARHT Media Inc., Clearview Resources Limited, and InvestPlus REIT; he is also a past director of Dealnet Capital Corp. With more than two decades of experience as director and advisor for both public and private companies, he has particular expertise in oil and gas, real estate, financial services, mining, and technology. He has also assisted companies in capital raising, mergers and acquisitions, debt restructurings, and risk management. These new board appointments are made as the company gears up to change its name to Chalice Brands (https://ibn.fm/QZfPO). “Throughout this turnaround over the last 18 months, we continue to gather momentum and galvanize management behind the Chalice brand,” said Golden Leaf CEO Jeff Yapp. “Our Chalice Farms stores and our Chalice chews are the pride of our business. As we put the Golden Leaf era behind us, this name change serves to symbolize our resurgence as a relevant contender in the US cannabis industry, driven by leadership in our home market of Oregon.” Golden Leaf Holdings is a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution, and retail, with seven dispensaries in Portland, Oregon. The company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness. Markets served include Oregon, California, Nevada, and Washington. For more information, visit the company’s website at www.GoldenLeafHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to GLDFF are available in the company’s newsroom at https://ibn.fm/GLDFF

• SBEV entered partnership with Johnson Brothers to increase Copa Di Vino and Pulpoloco Sangria distribution in North Carolina
• SBEV leverages superior production, supply chain efficiencies, global distribution capabilities to rapidly develop, accelerate pre-existing brands for profitable exits
• Johnson Brothers recently expanded distribution footprint through Mutual Distributing Co. acquisition

Splash Beverage Group (OTCQB: SBEV), a holding company with a leading portfolio of beverage brands, recently announced entry into the North Carolina market through a new partnership with Johnson Brothers – a leading wine, spirits and beer distributor (https://ibn.fm/X2J7C). The agreement includes the distribution of Copa di Vino and Pulpoloco Sangria, two of the company’s leading beverage innovations that combine product quality, technological innovation and proven branding power. Residents of South Carolina will soon have wide access to SBEV’s Copa di Vino – a premium “wine by the glass” product that can be easily consumed anywhere without requiring a bottle opener or corkscrew. The brand made headlines decades ago on Shark Tank after its founder turned down multiple offers, choosing instead to branch out independently and make tens of millions of dollars on his own before selling the business to SBEV (https://ibn.fm/3Is5j). Its unique packaging is rivaled by SBEV’s premium Pulpoloco Sangria – a fine Sangria imported from Spain using a premium blend of Spanish ingredients. Eco-friendly and biodegradable, Pupoloco Sangria is aseptically filled and packaged in an eco-friendly CARTOCAN(R) container for flavor enhancement and sustainable disposal. Johnson Brothers (“JB”) has represented industry-leading suppliers as well as notable local brands for nearly 70 years. Along with extensive coverage across North Carolina, the company’s distribution footprint surged once again with the recent acquisition of Mutual Distributing Co. – one of the most extensive wine and beer distributors in the state. “The partnership with Johnson has our wine/sangria brands joining the most elite domestic and international wines covered by JB in North Carolina,” said SBEV President and Chief of Marketing Bill Meisner. “With 40 years’ experience distributing wine, specialty beers and spirits, we’ve found an ideal partner for this region, complementing our existing distribution in this region. “Shareholders and consumers alike will recognize a rapid entry to market via established partners that give us a leg up in entering markets throughout the country toward expedited growth and overall exposure for our unique portfolio of beverage brands,” Meisner concluded. SBEV seeks out trendy brands with special characteristics that include superior ingredients, top quality and health benefits. Along with Copa Di Vino and Pulpoloco Sangria, SBEV’s portfolio also includes TapouT Performance – a natural isotonic hydration & recovery sports drink, and Salt Naturally Flavored Tequila – a fine tequila crafted from handpicked, 100% pure blue agave plants from the mountains of Jalisco, one of the country’s most fertile agave-growing regions. SBEV strives to maintain high performance standards with a focus on execution, ensuring that distributors and retail partners achieve and exceed all goals. The company’s growth strategy is characterized by superior production, supply chain efficiencies and global distribution capabilities that are leveraged to rapidly develop and accelerate pre-existing brands that can be profitably exited for cash events. For more information, visit the company’s website at www.SplashBeverageGroup.com. NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

• Strategic licensing agreement with Phenome One key to Pac Roots success
• Pac Roots has unlimited access to one of Canada’s largest live genetic libraries for growing, breeding, cloning use
• Company’s passion is preserving excellence of elite strains while introducing highest quality of new strains

From the beginning, Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) has been committed to quality. In fact, the company’s motto — the Future of Genetics: Quality over Quantity — captures the company’s unique expertise and focus on elite genetic development (https://ibn.fm/4MnYf). One of the key components of Pac Roots Cannabis’s business model is its strategic licensing agreement with Phenome One, a full-service cannabis farming company focused on elite strain selective breeding (https://ibn.fm/K2W7H). Through this invaluable agreement, Pac Roots gains unlimited access to one of Canada’s largest live genetic libraries for growing, breeding and cloning use. Phenome One’s library features more than 350 cultivars — an estimated 50 of which are in the super elite category — and each one has been laboratory analyzed and field tested for more than three decades. This vast resource of both information and cultivars provides unprecedented potential for Pac Roots Cannabis to deliver on its mission to provide the finest genetics to its consumers. “Preserving the excellence of our elite strains while introducing the highest quality of new strains to the public is our passion,” Pac Roots Cannabis states on its website. “Genetic variation and stability are the foundation that drives the decision making for our business.” At least part of Phenome’s expertise lies in its state-of-the-art growing systems that are carefully designed to incorporate proprietary nutrient regimes with experience in all growing mediums. Phenome One’s elite line of rigorously tested production cultivars consists of hundreds of cultivars that have a minimum of nine commercial production cycles. For example, the company’s signature cultivar, Phenome OG, took six years of selective breeding to produce. A powerful indica dominant strain, the plant features THC levels in the 27–32% range and high levels of the terpene Myrcene; its CGB levels also consistently reach more than 1%. Relying on Phenome’s years of choosing only the most elite genotype and phenotype expressions, Pac Roots is able to offers its customers the highest-quality cultivar possible. Whether it’s a CBD-dominant plant with a rare terpene profile or a soaring 30%+ THC giant, Phenome One has a cultivar suited for every customer. Pac Roots Cannabis is dedicated to delivering the finest genetics to Canadians. In doing so, the company preserves the excellence of its elite strains while introducing the highest quality of new strains to the public. Genetic variation and stability form the foundation that drives the decision making for the Pac Roots business. While some companies may strive to be the largest cannabis grower, Pac Roots Cannabis believes that the quality of the cannabis is paramount. The demand for premium products has never been higher, and Pac Roots Cannabis is ideally positioned to be a leader in the premium cannabis space. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Projections by various research firms indicate that the electric vehicle (“EV”) and fintech markets will grow through the coming years
• The EV industry will witness a steady increase in the penetration of EVs in three key markets in which IDEX, through its Ideanomics Mobility division, operates
• The global fintech industry is projected to grow at a 23.58% CAGR from 2021 to 2025, while the US fintech market is estimated to witness a CAGR of 8.6% from 2019 through to 2024, and the Ideanomics Capital division focuses on fintech solutions

A recent electric vehicle (“EV”) market publication by J.P. Morgan (NYSE: JPM) Global Research showed that EV penetration was gradually growing in North America, Europe, and China. The report projected that the penetration in the North American market would increase to 4% in 2020, up from 3% in 2019. In comparison, the European and Chinese markets were forecasted to witness a more rapid growth, fueled by an enabling regulatory environment, higher spending power and the prospects of a future that merges autonomous driving with green vehicles.

The Chinese EV industry is currently in the acceleration stage, which started in 2020 and is expected to last until 2025, when the EV penetration is likely to cap at 20%, up from 5% in 2019. In Europe, five countries, namely the UK, Spain, Italy, Germany and France, dominate the EV space, taking up 63% of the EV volumes across Europe. Per the J.P. Morgan report, EV penetration in 2020 in these countries was about 6%, up from 1.6% in 2019. Further, EV sales had reached 27% of the total, compared to 8% in 2019 (https://ibn.fm/Am4lS).

While the COVID-19 pandemic slowed the demand for both passenger and commercial EVs, a separate report by Bloomberg New Energy Finance (“BNEF”) indicates that the demand will resurge and maintain an upward trajectory through the coming years, at both regional and global levels (https://ibn.fm/WEXb3).

For Ideanomics (NASDAQ: IDEX), a global company with a foothold in each of these three markets, these positive trends and statistics effectively mean that it is uniquely positioned to thrive well into the future. IDEX has been rapidly expanding its Mobility division through new acquisitions and investments. As a result, it has amassed a broad portfolio of EV products, including buses, EV tractors, trucks, two-wheelers and three-wheelers, on the vehicular end of the spectrum, as well as wireless charging solutions and battery and charging technology design and development, on the other. Currently, the Mobility unit consists of over five companies based in various jurisdictions.

“We have a unique view across what we believe is the EV value chain because we have operations in China, South Asia, in Malaysia, in Europe and in North America,” CEO Alf Poor said during a recent webinar (https://ibn.fm/KGNeW).

IDEX’s second division, aptly named Ideanomics Capital, currently comprises companies offering disruptive fintech solutions covering a broad range of financial services. As with the Mobility unit, Ideanomics Capital is equally poised to benefit from the projected growth in the fintech sector.

Before the pandemic, the adoption of fintech solutions was increasing twofold every two years, reaching 64% in 2019, up from 16% in 2015 (https://ibn.fm/4MfP8). Nonetheless, the World Bank observed that the fintech industry remained largely unaffected by the vagaries of the pandemic and, in fact, reported double-digit growths in some areas (https://ibn.fm/Gnl7O).

This momentum is likely to continue through the mid-2020s as indicated by a Research and Markets forecast, which expects the global fintech market to grow at a CAGR of 23.58% from 2021 to 2025 (https://ibn.fm/SsiJJ). Locally, the US fintech market is projected to grow at an 8.6% CAGR from 2019 to 2024 (https://ibn.fm/T0m2w).

For more information, visit the company’s website at www.Ideanomics.com.

NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• Agreement calls for Cybin, Catalent to work together to develop novel therapy for treatment-resistant psychiatric disorders
• Cybin looking to identify fast-acting, shorter-duration formulations of CYB003
• Delivering CYB003 through Catalent ODT could provide significant benefits

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products (https://ibn.fm/nQdpg). The agreement, which is scheduled to start this month, calls for the two companies to work together to potentially develop a novel, fast-acting therapy for treatment-resistant psychiatric disorders.

“We are excited to partner with the team at Catalent with the aim of developing fast-acting, shorter-duration formulations of CYB003, recently acquired as part of our acquisition of Adelia Therapeutics,” said Cybin CEO Doug Drysdale. “Our focus on reducing the need for health system resources, such as in-clinic therapist time, is an important part of our goal to create scalable, more accessible treatments for mental health disorders.”

As part of the agreement, Cybin plans on applying Catalent’s proprietary Zydis(R) orally disintegrating tablet (“ODT”) technology to the delivery of CYB003, Cybin’s novel deuterated tryptamine, as a potential therapy for treatment-resistant psychiatric disorders. One of the world’s best-performing ODTs, the proprietary Zydis technology creates a freeze-dried tablet that disperses its contents almost instantly in the mouth without needing water.

Delivering CYB003 in such a way provides significant potential benefits, including allowing for pre-gastric delivery and preventing first-pass metabolism, which could potentially improve the pharmacokinetic profile of the drug. The partnership will include feasibility studies that include manufacturing and analytical testing of ODT doses containing varying quantities of CYB003 alongside different excipients.

“We look forward to working with Cybin to potentially develop a novel and fast-acting therapy for treatment-resistant psychiatric disorders,” said Catalent president of oral and specialty delivery Jonathan Arnold. “The Zydis platform is an ideal technology to leverage for this type of drug formulation, as pre-gastric absorption is crucial for efficacy.”

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Even major players in the CBD market do not offer detailed and verifiable study results to effectively differentiate their products on the basis of meaningful clinical findings, essentially exploiting the “natural” label without any R&D efforts
• This industry deficiency represents immense opportunities for R&D-driven companies such as Green Hygienics
• Green Hygienics intends to use its intellectual and capital resources to establish and apply state-of-the-art research and development to a new generation of cannabinoid-based products having specifically assessed health-wellness efficacies

CBD Reality Check  Interest in the therapeutic use of hemp-derived nonintoxicating cannabinoids, such as cannabidiol (“CBD”) and cannabigerol (“CBG”), has reached a fever-pitch in recent years followed by the early-stage preclinical discoveries surrounding the tentative functional role of the endocannabinoid system (“ECS”). CBD received a further popular validation since U.S. FDA approved Epidiolex(R) as adjunctive therapy for pediatric patients with drug-resistant epilepsy. During the last 5-8 years, CBD has been highly acclaimed and heavily hyped. Its medicinal qualities are perceived as limitless by some, and its non-psychoactive nature makes it “suitable” for just about anyone, as it has been claimed by many activists and business entities. The broad-ranging claims of CBD therapeutic utilities are endless, while monopolistic entrepreneurs are rushing the industry in droves, touting first-to-market achievements over quality, research-backed product offerings. Current Status-Quo and Future Expectations  A case can be made that the majority of CBD companies simply ignore the lack of efficacy in their products to avoid potentially undermining their commercial utility, preferring to exploit the “natural” label without any R&D efforts, the very efforts that could establish important evidence-based credibility for their products. Companies marketing products containing CBD have been over-exuberant in their claims about its effectiveness. They have been guilty of illegal, sleight-of-hand, exploiting public enthusiasm over cannabis/hemp by portraying all cannabinoids as not only safe but capable of ameliorating the symptoms of many serious medical conditions. Consequently, the reputation of CBD as a universal “cure-all” puts this still promising substance in the same class as other “natural” panaceas, where anecdotal cases and overwhelmingly biased testimonials supersede the proper efficacy evaluation of already marketed CBD finished products. Notwithstanding, while CBD and other hemp-derived cannabinoids remain a formally unproven therapeutic option with a known mechanism of action, physicians and holistic health/wellness practitioners remain open to the possible future role of these products in the field of alternative management and prophylaxis of different health conditions such as chronic inflammation and pain. Emerging companies like Green Hygienics Holdings (OTCQB: GRYN) have an opportunity to paint a brighter future for the CBD industry and provide a research-based platform for which these physicians and holistic health/wellness practitioners can specifically select and recommend beneficial products meaningful to their intended purpose of providing patient relief. To recommend a particular cannabinoid-based product to patients and wellness-oriented end-users, those practitioners need to adequately analyze specific information and study reports on the experimentally assessed systemic exposure, bioavailability and targeted efficacy of a particular product, instead of focusing solely on the certificate of analysis (“COA”) that verifies only the concentration of bio-active ingredients and absence of harmful contaminants. A very brief survey gathered from the published scientific and commercial papers or conference presentations indicates that even the major players in the CBD market do not possess such study results and reports to differentiate and promote their products based on at least preclinical and/or exploratory clinical study findings. Green Hygienics is Poised to Address the Current State of the Industry On the other hand, this particular status-quo represents the immense opportunities for R&D-driven companies like Green Hygienics in an everchanging cannabinoid market landscape. Physicians and holistic health/wellness practitioners are looking for more advanced, evidence-based cannabinoid products with high, unparalleled, and most importantly unbiased therapeutic efficacies of achievable health-beneficial effects. Green Hygienics is an enterprise that has developed a model resting on this exact premise of bringing evidence-based cannabinoid products to market, backed with unbiased therapeutic efficacies, through research-based evidence. The company aims to be a leader in compliance and capabilities in the hemp and cannabinoid supply marketplace. By leveraging state of the art technologies, the company intends to open up a whole new world of fully characterized novel cannabinoids and targeted bio-delivery technologies never before explored. Green Hygienics is aimed at maximizing the use of intellectual and capital resources. Therefore, the Company has decided to move forward with the establishment of a state-of-art biotechnology R&D facility to focus its resources on the rational and innovative design of formulations, development and experimental evaluation of the new generation cannabinoid-based products with superior bioavailability and specifically assessed health-wellness efficacies. Discovery and development of highly efficacious cannabinoid-based products is a global task that is based on multidisciplinary approaches, collaborations, and partnerships. Therefore, Green Hygienics is building its collaborative platform with several academic institutions, both domestically and abroad, to utilize well established endocannabinoid system (“ECS”) target screening models and develop customized wellness products addressing ECS deficiencies. The ultimate goal is to develop and promote highly functional, experimentally assessed and supported efficacious nutraceutical products that will be trusted by medical communities, physicians, holistic health practitioners, and wellness-oriented end users. For a more in-depth exploration on this topic, please refer to this paper published in Nutritional Outlook by Levan Darjania, PhD. (https://ibn.fm/Sf9eH). About Green Hygienics Holdings Green Hygienics Holdings Inc. (OTCQB: GRYN) is a California-based innovative, technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids. The company’s corporate mission is to adhere to the highest standards of operations in consistently delivering safe and premium-quality products to consumers as well as to partner with CPG (consumer packaged goods) and pharmaceutical companies. The company intends to be a leader in compliances and capabilities in the hemp and cannabinoid supply marketplace. Using state-of-the-art technologies, Green Hygienics intends to open a whole new world of novel cannabinoids and targeted bio-delivery technologies never before explored, solving the issues of stability, pharmacokinetics, biological tissue penetration and bioavailability. GRYN is building a team of visionary agrotechnology, pharmaceutical and life scientists working at the intersection of nutraceutical, cosmeceutical and pharmaceutical technologies with a goal to improve lives. View GRYN’s corporate video and follow the company on Facebook, Twitter and Linkedin. Corporate Communications: Heidi Thomasen IR@GreenHygienics.com Toll Free 1.855.802.0299 For more information, visit the company’s website at www.GreenHygienics.com. NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

• Universal desire, worldwide market at heart of the Happy Co.
• The Happy Co. offers functional beverages, capsules, patches, and other products—all carefully designed and formulated to deliver benefits
• Happiness is a lifestyle that the Happy Co. is working to support from every angle

One of the fastest-growing companies in the social-marketing and direct-selling industries, the Happy Co., a subsidiary of Sharing Services Global (OTCQB: SHRG), is building an entire business around happiness. “Happiness is a universal desire,” says the company, which notes that “the world is our market [and] literally every person on earth wants what we offer” (https://ibn.fm/hwP9L). Based on the ideal that everyone deserves to be happy, the Happy Co. has created a business model to make happiness happen for everyone involved with the company. The Happy Co. offers functional beverages, capsules, patches, and other products—all carefully designed and formulated to elevate mood, boost energy, reduce stress, enhance sleep, help with weight management, and make consumers look and feel happier. While the company’s focus on making happiness happen starts with exclusive, extraordinary products, that is only the beginning. Happiness is a lifestyle, one that the Happy Co. is working to support from every angle. From the first sip of morning coffee, this social-marketing innovator is looking for every opportunity throughout the day to harness the power of happiness. The Happy Co. offers its community members products and opportunities designed to surprise and delight—and instill happiness. The Happy Co. is the new brand identity of SHRG’s wholly owned subsidiaries Elevacity Holdings LLC and Elevacity U.S. LLC. (https://ibn.fm/xX6QJ). The rebranding involved a complete rehaul of both the consumer-facing website, which was created to be the place where customers purchase Happy Co. products, and the business website, which is designed to be the hub showcasing the business opportunity. “The Happy Co. is not just a name; it is the best descriptor of our mission,” said Bo Short, CEO of Elevacity Holdings LLC and Elevacity International Holdings LLC. “It directly mirrors our values and purpose of sharing happiness through products and experiences that elevate lives. Our brand partners and our customers live this experience every day. This new branding is an important step as we begin our global expansion in 2021. It connects perfectly to our enhanced business platform and ever-growing ecosystem of products.” The new branding is launched as an integral part of Sharing Services’ efforts to accelerate growth in the international landscape. Designed to emanate a pleasant feeling, the branding works hand in hand with the company’s offering developed to fuel customers for the good life. With the Happy Co. branding firmly in place, SHRG is proving again that it is a quick mover that adjusts effectively to emerging market demand as studies show that health awareness and community are key building blocks of new consumer behavior. For more information, visit www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Brokerage firm H.C. Wainwright & Co. recently released report featuring UEC, reiterates Buy rating
• Recent drilling activities at UEC’s Burke Hollow in situ recovery (“ISR”) project show strong results, potential for further resource growth
• UEC well-financed to aggressively pursue key developmental targets, the Company has over $110 million in cash, equity and inventory holdings
• UEC is production ready with four fully licensed uranium projects and a state-of-the-art Central Processing plant with a combined production profile of 4 million pounds of uranium per year

Uranium Energy (NYSE American: UEC), a Corpus Christi, Texas-based uranium mining and exploration company, was recently featured in an H.C. Wainwright & Co. (Wainwright) equity research report that covered wellfield development, resource delineation and company financial updates (https://ibn.fm/rhR2m). Wainwright analysts reiterated their Buy rating for UEC’s stock based on a discounted cash flow (“DCF”) model of future operations and in situ asset values

“We are reiterating our Buy rating on UEC and our PT of $5,” reads the research report. “Our valuation remains based on a DCF of future operations for the firm, utilizing our recently revised 7.5% discount rate. We then add an in situ value of $75.0M for UEC’s Reno Creek assets, $41.5M for Alto Parana’s resources, and an additional $40.0M for Paraguay and UEC’s other exploration stage assets. We continue to believe that these figures remain inline with similar projects throughout our coverage universe to which we assign equal geopolitical risk factors.”

Wainwright backs its recommendation by UEC’s recent drilling activities at its Burke Hollow ISR project in South Texas, where strong results demonstrated promising growth potential (https://ibn.fm/avrBj). Wainwright also detailed the closure of UEC’s recent offering that grossed $12 million, with expectations that the net proceeds will be applied towards additional uranium purchases and general working capital requirements. Accordingly, the report states that UEC’s total cash, equity, and inventory holdings of $110 million can fully fund its physical uranium initiative that stands at 2.105 million pounds at a weighted average price of about $30 per pound, with deliveries expected between March 2021 and December 2022.

Favorable market predictions in the Wainwright report include growth in global demand, increased domestic demand from the U.S. Uranium Reserve, and long-term rising uranium prices that may drive positive production decisions at one or more of UEC’s projects.

Founded in 2003, Uranium Energy Corp. is a U.S.-based uranium mining and exploration company that controls one of the country’s largest historical uranium exploration and development databases. By leveraging historical exploration data, UEC has been able to target and acquire properties that have already been subject to exploration and development by senior energy firms in the past, positioning it favorably to capitalize on rising global uranium demand while using green technology that favors the environment. The Company has a near term extraction profile of 4 million pounds of U3O8 per year from its low-cost South Texas and Wyoming ISR projects.  With the largest U.S. resource base of fully permitted and environmentally friendly ISR projects in Texas and Wyoming, UEC is ideally positioned to be the leader in a resurgence of domestic uranium mining.

For more information, visit the company’s website at www.UraniumEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at https://ibn.fm/UEC

• PlantX Life launches new refrigerated and frozen food product lines as consumers seek healthier and sustainable food options amid the pandemic
• PLTXF has also switched to green packaging, which marks the first part of its newly launched sustainability initiative
• PLTXF appears poised for long-term growth as studies show the shift in consumer trend is here to stay

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) is set to thrive as consumers change habits amid the pandemic. As a marketplace providing consumers all things plant-based, the company has launched a new refrigerated and frozen food product line to capitalize on the current market environment where consumers increasingly turn to healthier and sustainable lifestyle choices. The pandemic has revealed that consumers changed the way they think about, purchase and consume their food, placing a much bigger emphasis on sustainability and health (https://ibn.fm/km4yj). Committed to early recognition of emerging market trends, PlantX Life was quick to adjust to these newly surfacing consumer trends. The company has recently launched a refrigerated and frozen food segment that offers high-quality fresh and frozen plant-based food products delivered at consumers’ door. The plant-based food industry was on the rise even before the pandemic, but the virus outbreak has propelled the sector to new heights. The new product addition provides convenient, yet premium plant-based food products targeted at consumers who value both comfort and wholesomeness when it comes to food. The plant-based brands represented include Beyond Meat, Impossible Foods, Miyokos, Follow Your Heart, Gardein, Tofurkey and Alpha Foods. The new products are now available in the ‘Frozen’ and ‘Refrigerated’ sections of the company’s United States e-commerce platform. The frozen section offers a wide selection of frozen food across multiple product categories such as appetizers, bread & dough, desserts, entrees & sides, fruit, meat alternatives, pizza and vegetables (https://ibn.fm/CVmZD). Refrigerated food assortments include beverages, bread, condiments & dressings, dairy & egg alternatives, dips and meat alternatives (https://ibn.fm/d6puM). With the addition of frozen and refrigerated items, PlantX Life will be able to provide a broad offering of products as a one-stop-shop for everything plant-based e-commerce platform. The newly added products will be available for shipping to Canadian customers later this year. Also available in the brick-and-mortar stores, these products offer consumers nutritious-rich fresh and frozen food selection across a range of specialized diets — from gluten-free, non-GMO, organic, soy-free, paleo-friendly, to keto-friendly, kosher, nut-free, allergen-free and sugar-free. Committed to promoting both the health of people and nature, PlantX Life now uses sustainable packaging to minimize the environmental impact of packaging waste of its products. The company partnered with Quebec-based company Colder Fresher Longer to introduce new packaging standards that will allow it to reduce the carbon footprint. This move marks just the beginning of PlantX’s plans to adopt broader sustainability practices as eco-friendly and ethical considerations have become an essential purchasing consideration for the modern consumer. The shift in consumer behavior favoring healthy and sustainable choices is not only widespread but most likely permanent. The overwhelming majority (75%) of consumers plan to eat and drink healthier due to the pandemic (https://ibn.fm/AHphO) and the change has become more pronounced one year later (https://ibn.fm/tQ1Hv). This indicates a fundamental, long-term shift in consumers’ attitudes toward health and wellness. The company’s business model based on the combination of e-commerce and health-focused plant-based food products appear to be a winning match for the current market environment and beyond. For more information, visit the company’s website at www.Investor.PlantX.com, and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF